BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 29495002)

  • 1. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
    Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
    Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
    Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
    Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
    Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
    Saha MN; Abdi J; Yang Y; Chang H
    Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
    Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
    Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
    Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overproduced CPSF4 Promotes Cell Proliferation and Invasion via PI3K-AKT Signaling Pathway in Oral Squamous Cell Carcinoma.
    Zhang M; Lin H; Ge X; Xu Y
    J Oral Maxillofac Surg; 2021 May; 79(5):1177.e1-1177.e14. PubMed ID: 33535057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
    Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
    Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
    Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways.
    Jiang JH; Pi J; Jin H; Cai JY
    J Cell Biochem; 2019 Mar; 120(3):3736-3746. PubMed ID: 30229997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.